Unknown

Dataset Information

0

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.


ABSTRACT: The use of tumor-derived proteins as cancer vaccines is complicated by tolerance to these self-antigens. Tolerance may be broken by immunization with activated, autologous, ex vivo generated and antigen-loaded, antigen-presenting cells (APC); however, targeting tumor antigen directly to APC in vivo would be a less complicated strategy. We wished to test whether targeted delivery of an otherwise poorly immunogenic, soluble antigen to APC through their mannose receptors (MR) would induce clinically relevant immunity.Two phase I studies were conducted with CDX-1307, a vaccine composed of human chorionic gonadotropin beta-chain (hCG-?) fused to an MR-specific monoclonal antibody, administered either locally (intradermally) or systemically (intravenously) in patients with advanced epithelial malignancies. An initial dose escalation of single-agent CDX-1307 was followed by additional cohorts of CDX-1307 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the Toll-like receptor (TLR) 3 agonist polyinosinic-polycytidylic acid (poly-ICLC) and TLR7/8 agonist resiquimod to activate the APC.CDX-1307 induced consistent humoral and T-cell responses to hCG-? when coadministered with TLR agonists. Greater immune responses and clinical benefit, including the longest duration of stable disease, were observed with immunization combined with local TLR agonists. Immune responses were induced equally efficiently in patients with elevated and nonelevated levels of serum hCG-?. Antibodies within the serum of vaccinated participants had tumor suppressive function in vitro. Toxicity consisted chiefly of mild injection site reactions.APC targeting and activation induce adaptive immunity against poorly immunogenic self-antigens which has implications for enhancing the efficacy of cancer immunotherapy.

SUBMITTER: Morse MA 

PROVIDER: S-EPMC3139834 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

Morse Michael A MA   Chapman Robert R   Powderly John J   Blackwell Kimberly K   Keler Tibor T   Green Jennifer J   Riggs Renee R   He Li-Zhen LZ   Ramakrishna Venky V   Vitale Laura L   Zhao Biwei B   Butler Stephen A SA   Hobeika Amy A   Osada Takuya T   Davis Thomas T   Clay Timothy T   Lyerly H Kim HK  

Clinical cancer research : an official journal of the American Association for Cancer Research 20110601 14


<h4>Purpose</h4>The use of tumor-derived proteins as cancer vaccines is complicated by tolerance to these self-antigens. Tolerance may be broken by immunization with activated, autologous, ex vivo generated and antigen-loaded, antigen-presenting cells (APC); however, targeting tumor antigen directly to APC in vivo would be a less complicated strategy. We wished to test whether targeted delivery of an otherwise poorly immunogenic, soluble antigen to APC through their mannose receptors (MR) would  ...[more]

Similar Datasets

| S-EPMC3547938 | biostudies-literature
| S-EPMC3746895 | biostudies-other
| S-EPMC10316682 | biostudies-literature
| S-EPMC4993816 | biostudies-other
| S-EPMC8355054 | biostudies-literature
| S-EPMC4163654 | biostudies-literature
| S-EPMC5334362 | biostudies-literature
| S-EPMC4304210 | biostudies-literature
| S-EPMC4637118 | biostudies-literature
| S-EPMC4591979 | biostudies-literature